Investors can contact the law firm at no cost to learn more about recovering their losses
LOS ANGELES, Nov. 01, 2023 (GLOBE NEWSWIRE) — The Portnoy Law Firm advises Tandem Diabetes Care, Inc. (“Tandem” or the “Company”) (NASDAQ: TNDM) investors that a lawsuit filed on behalf of investors that purchased Tandem securities between August 3, 2022 and November 2, 2022, inclusive (the “Class Period”)
Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: lesley@portnoylaw.com, to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.
- As per the allegations in the Complaint, Tandem is a global medical technology company specializing in the development, manufacturing, and marketing of various consumer technologies and software designed for managing diabetes care at home. Their flagship product, the “t:slim X3,” is an FDA-approved at-home insulin pump, and the company also offers web-based applications to assist users in monitoring and treating diabetes.
- The Plaintiff asserts that the Defendants provided sales projections for Tandem for the year 2022, ranging from “$835 million to $845 million,” with anticipated annual growth of “19 percent to 20 percent” compared to 2021. The Plaintiff contends that these statements were materially misleading and concealed important adverse facts.
- However, on November 2, 2022, Tandem significantly revised its 2022 sales forecast downward to a range of “$800 to $805 million.” This substantial adjustment was attributed to factors such as heightened competition in the diabetes care industry, complications stemming from the COVID pandemic, and broader economic influences like inflation.
- Following this announcement, Tandem’s common stock experienced a decline of $14.57 per share, which amounted to approximately 28.37%, ultimately closing at $36.77 per share on November 3, 2022.
Please visit our website to review more information and submit your transaction information.
The Portnoy Law Firm represents investors in pursuing claims against caused by corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.
Lesley F. Portnoy, Esq.
Admitted CA and NY Bar
lesley@portnoylaw.com
310-692-8883
www.portnoylaw.com
Attorney Advertising
- Orezone Gold Reports First Quarter 2025 Results - May 14, 2025
- Polpharma Group Calls for Urgent Action to Protect early equitable access to medicines for European patients - May 14, 2025
- SFL – First Quarter 2025 Results - May 14, 2025
